Gregory S Day1, Tae Sung Lim1, Jason Hassenstab1, Alison M Goate1, Elizabeth A Grant1, Catherine M Roe1, Nigel J Cairns1, John C Morris2. 1. From the Charles F. and Joanne Knight Alzheimer Disease Research Center (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), Department of Neurology (G.S.D., T.S.L., J.H., C.M.R., N.J.C., J.C.C.), Division of Biostatistics (E.A.G.), and Department of Pathology and Immunology (N.J.C.), Washington University School of Medicine (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), St. Louis, MO; Ajou University School of Medicine (T.S.L.), Suwon, Republic of Korea; and Icahn School of Medicine at Mount Sinai (A.M.G.), New York, NY. 2. From the Charles F. and Joanne Knight Alzheimer Disease Research Center (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), Department of Neurology (G.S.D., T.S.L., J.H., C.M.R., N.J.C., J.C.C.), Division of Biostatistics (E.A.G.), and Department of Pathology and Immunology (N.J.C.), Washington University School of Medicine (G.S.D., T.S.L., J.H., A.M.G., E.A.G., C.M.R., N.J.C., J.C.M.), St. Louis, MO; Ajou University School of Medicine (T.S.L.), Suwon, Republic of Korea; and Icahn School of Medicine at Mount Sinai (A.M.G.), New York, NY. jcmorris@wustl.edu.
Abstract
OBJECTIVE: To identify clinical features that reliably differentiate individuals with cognitive impairment due to corticobasal degeneration (CBD) and Alzheimer disease (AD). METHODS: Clinical features were compared between individuals with autopsy-proven CBD (n = 17) and AD (n = 16). All individuals presented with prominent cognitive complaints and were evaluated annually with semistructured interviews, detailed neurologic examinations, and neuropsychological testing. RESULTS: Substantial overlap was observed between individuals with dementia due to CBD and AD concerning presenting complaints, median (range) duration of symptoms before assessment (CBD = 3.0 [0-5.0] years, AD = 2.5 [0-8.0] years; p = 0.96), and median (range) baseline dementia severity (Clinical Dementia Rating Sum of Boxes: CBD = 3.5 [0-12.0], AD = 4.25 [0.5-9.0], p = 0.49). Subsequent emergence of asymmetric motor/sensory signs, hyperreflexia, gait abnormalities, parkinsonism, falls, urinary incontinence, and extraocular movement abnormalities identified individuals with CBD, with ≥3 discriminating features detected in 80% of individuals within 3.1 years (95% confidence interval 2.9-3.3) of the initial assessment. Individuals with CBD exhibited accelerated worsening of illness severity and declines in episodic memory, executive functioning, and letter fluency. Semiquantitative pathologic assessment revealed prominent tau pathology within the frontal and parietal lobes of CBD cases. Comorbid AD neuropathologic change was present in 59% (10 of 17) of CBD cases but did not associate with the clinical phenotype, rate of dementia progression, or dementia duration. CONCLUSIONS: CBD may mimic AD dementia early in its disease course. Interval screening for discriminating clinical features may improve antemortem diagnosis in individuals with CBD and prominent cognitive symptoms.
OBJECTIVE: To identify clinical features that reliably differentiate individuals with cognitive impairment due to corticobasal degeneration (CBD) and Alzheimer disease (AD). METHODS: Clinical features were compared between individuals with autopsy-proven CBD (n = 17) and AD (n = 16). All individuals presented with prominent cognitive complaints and were evaluated annually with semistructured interviews, detailed neurologic examinations, and neuropsychological testing. RESULTS: Substantial overlap was observed between individuals with dementia due to CBD and AD concerning presenting complaints, median (range) duration of symptoms before assessment (CBD = 3.0 [0-5.0] years, AD = 2.5 [0-8.0] years; p = 0.96), and median (range) baseline dementia severity (Clinical Dementia Rating Sum of Boxes: CBD = 3.5 [0-12.0], AD = 4.25 [0.5-9.0], p = 0.49). Subsequent emergence of asymmetric motor/sensory signs, hyperreflexia, gait abnormalities, parkinsonism, falls, urinary incontinence, and extraocular movement abnormalities identified individuals with CBD, with ≥3 discriminating features detected in 80% of individuals within 3.1 years (95% confidence interval 2.9-3.3) of the initial assessment. Individuals with CBD exhibited accelerated worsening of illness severity and declines in episodic memory, executive functioning, and letter fluency. Semiquantitative pathologic assessment revealed prominent tau pathology within the frontal and parietal lobes of CBD cases. Comorbid AD neuropathologic change was present in 59% (10 of 17) of CBD cases but did not associate with the clinical phenotype, rate of dementia progression, or dementia duration. CONCLUSIONS: CBD may mimic AD dementia early in its disease course. Interval screening for discriminating clinical features may improve antemortem diagnosis in individuals with CBD and prominent cognitive symptoms.
Authors: Naomi Kouri; Melissa E Murray; Anhar Hassan; Rosa Rademakers; Ryan J Uitti; Bradley F Boeve; Neill R Graff-Radford; Zbigniew K Wszolek; Irene Litvan; Keith A Josephs; Dennis W Dickson Journal: Brain Date: 2011-09-20 Impact factor: 13.501
Authors: I Litvan; Y Agid; C Goetz; J Jankovic; G K Wenning; J P Brandel; E C Lai; M Verny; K Ray-Chaudhuri; A McKee; K Jellinger; R K Pearce; J J Bartko Journal: Neurology Date: 1997-01 Impact factor: 9.910
Authors: B F Boeve; D M Maraganore; J E Parisi; J E Ahlskog; N Graff-Radford; R J Caselli; D W Dickson; E Kokmen; R C Petersen Journal: Neurology Date: 1999-09-11 Impact factor: 9.910
Authors: Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann Journal: Acta Neuropathol Date: 2007-06-20 Impact factor: 17.088
Authors: John S K Kauwe; Carlos Cruchaga; Kevin Mayo; Chiara Fenoglio; Sarah Bertelsen; Petra Nowotny; Daniela Galimberti; Elio Scarpini; John C Morris; Anne M Fagan; David M Holtzman; Alison M Goate Journal: Proc Natl Acad Sci U S A Date: 2008-06-09 Impact factor: 11.205
Authors: Shunsuke Koga; Adam Parks; Koji Kasanuki; Monica Sanchez-Contreras; Matthew C Baker; Keith A Josephs; J Eric Ahlskog; Ryan J Uitti; Neill Graff-Radford; Jay A van Gerpen; Zbigniew K Wszolek; Rosa Rademakers; Dennis W Dickson Journal: Mov Disord Date: 2017-10-30 Impact factor: 10.338
Authors: Ryoko Ihara; Benjamin D Vincent; Michael R Baxter; Erin E Franklin; Jason J Hassenstab; Chengjie Xiong; John C Morris; Nigel J Cairns Journal: Ann Neurol Date: 2018-10-25 Impact factor: 10.422
Authors: Nobutaka Sakae; Octavio A Santos; Otto Pedraza; Irene Litvan; Melissa E Murray; Ranjan Duara; Ryan J Uitti; Zbigniew K Wszolek; Neill R Graff-Radford; Keith A Josephs; Dennis W Dickson Journal: Neurology Date: 2020-06-09 Impact factor: 9.910